These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome. Andrews EJ; Martini AC; Head E Front Neurosci; 2022; 16():954999. PubMed ID: 36033603 [TBL] [Abstract][Full Text] [Related]
7. Untangle the mystery behind DS-associated AD - Is APP the main protagonist? Elangovan A; Babu HWS; Iyer M; Gopalakrishnan AV; Vellingiri B Ageing Res Rev; 2023 Jun; 87():101930. PubMed ID: 37031726 [TBL] [Abstract][Full Text] [Related]
8. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613 [TBL] [Abstract][Full Text] [Related]
9. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555 [TBL] [Abstract][Full Text] [Related]
10. Common genetic signatures of Alzheimer's disease in Down Syndrome. Sharma A; Chunduri A; Gopu A; Shatrowsky C; Crusio WE; Delprato A F1000Res; 2020; 9():1299. PubMed ID: 33633844 [No Abstract] [Full Text] [Related]
11. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521 [TBL] [Abstract][Full Text] [Related]
12. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060 [TBL] [Abstract][Full Text] [Related]
13. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro. Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849 [TBL] [Abstract][Full Text] [Related]
14. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease. Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007 [TBL] [Abstract][Full Text] [Related]
15. Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Condello C; Maxwell AM; Castillo E; Aoyagi A; Graff C; Ingelsson M; Lannfelt L; Bird TD; Keene CD; Seeley WW; Perl DP; Head E; Prusiner SB Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2212954119. PubMed ID: 36343257 [TBL] [Abstract][Full Text] [Related]
16. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome. Drummond E; Kavanagh T; Pires G; Marta-Ariza M; Kanshin E; Nayak S; Faustin A; Berdah V; Ueberheide B; Wisniewski T Acta Neuropathol Commun; 2022 Apr; 10(1):53. PubMed ID: 35418158 [TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease like neuropathology in Down syndrome cortical organoids. Zhao HH; Haddad GG Front Cell Neurosci; 2022; 16():1050432. PubMed ID: 36568886 [No Abstract] [Full Text] [Related]
18. Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease. Tcw J; Goate AM Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28003277 [TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642 [TBL] [Abstract][Full Text] [Related]
20. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]